Celldex Therapeutics
Price & Volume
Stats
See more52W Range | $14.40-$31.29 |
Market Cap | $2B |
Shares Short | 9M |
Financials
See moreRevenue (12 Mos) | $2.5M |
Revenue Growth (YoY) | -70.8% |
Gross Profit (12 Mos) | -$214M |
Diluted EPS | -$3.38 |
News
See moreYahoo Finance • 11 hours ago
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
Yahoo Finance • yesterday
Celldex Therapeutics Stock Earns 88 RS Rating
Yahoo Finance • 3 days ago
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
Yahoo Finance • 19 days ago
Celldex to Present at Upcoming Investor Conferences
About
CEO | Mr. Anthony S. Marucci M.B.A. |
CFO | Mr. Sam Martin CPA |
Address | Perryville III Building, Hampton, NJ, United States, 08827 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 186 |
